Participating in the CIIE for four consecutive years, Zeiss challenges the limit of imagination with cutting-edge technology
Shanghai, China, October 27, 2021 – Zeiss will make its debut at the China International Import Expo (“CIIE”) for the fourth consecutive year under the theme of “Challenging the Limits of Imagination”. This year, ZEISS booth located in Hall 3 3A5-001 named its two exhibition areas with “Break through scientific boundaries, define future innovation” and “Challenge quality life, foresee more possibilities”, and will exhibit semiconductor manufacturing technology, industrial quality A range of innovative products and solutions in four business areas related to the research, medical technology and consumer optics markets.
Maximilian Foerst, President of Zeiss Greater China, said: “This year is the fourth time for Zeiss to participate in the CIIE, and it also marks the 175th anniversary of Zeiss’ establishment. We hope to build a wider partnership through the platform of the CIIE and further integrate into China’s ‘double At the same time, we also hope to review the history of Zeiss together with partners from all walks of life, continue to promote local innovation cooperation, and continue to challenge the limits of imagination.”
Pushing the boundaries of science and defining future innovations
The “14th Five-Year Plan” clarifies the long-term goals of scientific research innovation and upgrading, and advanced microscopic imaging technology plays an indispensable role in promoting breakthroughs in scientific research projects. In this sub-exhibition, ZEISS will showcase a series of leading microscopy imaging products to help scientific research and innovation in many fields. These include the Axioscope 5 optical microscope for materials science research, the Primostar 3 compact microscope for teaching and routine experiments, and the Stemi 508 high-efficiency practical stereo microscope for routine experiments and industrial inspections.
Semiconductor manufacturing technology and industrial quality solutions will also be featured in the exhibition area. Zeiss is actively responding to local needs, continuously breaking the technological limits and improving product quality through innovative solutions, and has made important contributions to the independent innovation and intelligent upgrading of China’s manufacturing industry, including semiconductors.
Challenge the quality of life, foresee more possibilities
As a major factor affecting the quality of public life, eye health is an important part of building a community of human health. In this sub-exhibition, ZEISS will exhibit its femtosecond laser corneal refractive therapy machine VisuMax, three-dimensional positioning optical system VISUFIT® 1000, refractive analyzer i.Profiler® Plus, true color HD ultra-wide-angle fundus camera CLARUS 500, The wide-angle vascular optical coherence tomography scanner, Cirrus HD-OCT 5000 AngioPlex, aims to bring the latest technology and the concept of “full life cycle eye health management” into the homes of ordinary people. Among them, VisuMax’s core technology “chirped pulse amplification technology” won the 2018 Nobel Prize in Physics, providing a new treatment method for refractive surgery.
On the other hand, as the situation of myopia prevention and control in Chinese children and adolescents is becoming more and more severe, Zeiss has set up a special team for the prevention and control of myopia in China, paying close attention to the high incidence of myopia in children and adolescents, the younger age of myopia, and the resulting eye diseases, schooling and employment, etc. question. The company plans to create an overall solution for myopia prevention and control through a digital platform, an excellent operation center and a new matrix of myopia products; at the same time, it will further deepen the cooperation with top local medical and scientific research institutions to jointly promote the standardization and precision of myopia diagnosis and treatment process. Zeiss will present the latest achievements of the project to the public at this CIIE.
As a global innovation pioneer in the field of optics and optoelectronics, since Zeiss entered China in 1957, it has always been close to local customers and industry development, and achieved common growth through close cooperation. With the world’s leading technological advantages, product portfolios and solutions covering the entire industry chain, and 175 years of innovation experience, Zeiss will continue to deepen the Chinese market and continue to create value for partners from all walks of life; Urgent needs for scientific research innovation, manufacturing upgrades and improving the quality of life.
About the ZEISS Group
ZEISS is a global technology pioneer in optics and optoelectronics. In the last fiscal year, the Zeiss Group’s annual revenue totaled 6.3 billion euros, covering the four business sectors of semiconductor manufacturing technology, industrial quality and research, medical technology, and optical consumer goods (data as of September 30, 2020).
ZEISS develops, manufactures and markets innovative industrial measurement and quality assurance solutions for its customers, microscopy solutions for biology and materials science, and medical technology solutions for ophthalmology and microsurgery. Zeiss is also the global industry benchmark for lithography technology, which is used by the chip industry in the manufacture of semiconductor components. In addition, innovative products such as eyeglass lenses, camera lenses and binoculars under the Zeiss brand are also available worldwide.
ZEISS’ product portfolio is in line with future growth areas such as digitalization, healthcare and smart manufacturing, and it also has a strong brand. With this, ZEISS is shaping the future of technology and continues to advance optics and related fields with its solutions. The company’s sustainable and substantial investment in research and development has laid a solid foundation for the company’s success, the continuous expansion of ZEISS technology and its market leadership. Zeiss invests 12% of its revenue in R&D – such a high level of R&D investment has a long tradition at Zeiss and is an investment in the future.
ZEISS has about 34,000 employees worldwide, about 30 production sites, nearly 60 sales and service companies and 27 R&D institutions in nearly 50 countries. The company was founded in Jena in 1846 and is headquartered in Oberkochen, Germany. Carl Zeiss AG is wholly owned (as of March 31, 2021) by the Carl Zeiss Foundation, which is dedicated to advancing science in Germany.
Participating in the CIIE for four consecutive years, Zeiss challenges the limit of imagination with cutting-edge technology
Shanghai, China, October 27, 2021 – Zeiss will make its debut at the China International Import Expo (“CIIE”) for the fourth consecutive year under the theme of “Challenging the Limits of Imagination”. This year, ZEISS booth located in Hall 3 3A5-001 named its two exhibition areas with “Break through scientific boundaries, define future innovation” and “Challenge quality life, foresee more possibilities”, and will exhibit semiconductor manufacturing technology, industrial quality A range of innovative products and solutions in four business areas related to the research, medical technology and consumer optics markets.
Maximilian Foerst, President of Zeiss Greater China, said: “This year is the fourth time for Zeiss to participate in the CIIE, and it also marks the 175th anniversary of Zeiss’ establishment. We hope to build a wider partnership through the platform of the CIIE and further integrate into China’s ‘double At the same time, we also hope to review the history of Zeiss together with partners from all walks of life, continue to promote local innovation cooperation, and continue to challenge the limits of imagination.”
Pushing the boundaries of science and defining future innovations
The “14th Five-Year Plan” clarifies the long-term goals of scientific research innovation and upgrading, and advanced microscopic imaging technology plays an indispensable role in promoting breakthroughs in scientific research projects. In this sub-exhibition, ZEISS will showcase a series of leading microscopy imaging products to help scientific research and innovation in many fields. These include the Axioscope 5 optical microscope for materials science research, the Primostar 3 compact microscope for teaching and routine experiments, and the Stemi 508 high-efficiency practical stereo microscope for routine experiments and industrial inspections.
Semiconductor manufacturing technology and industrial quality solutions will also be featured in the exhibition area. Zeiss is actively responding to local needs, continuously breaking the technological limits and improving product quality through innovative solutions, and has made important contributions to the independent innovation and intelligent upgrading of China’s manufacturing industry, including semiconductors.
Challenge the quality of life, foresee more possibilities
As a major factor affecting the quality of public life, eye health is an important part of building a community of human health. In this sub-exhibition, ZEISS will exhibit its femtosecond laser corneal refractive therapy machine VisuMax, three-dimensional positioning optical system VISUFIT® 1000, refractive analyzer i.Profiler® Plus, true color HD ultra-wide-angle fundus camera CLARUS 500, The wide-angle vascular optical coherence tomography scanner, Cirrus HD-OCT 5000 AngioPlex, aims to bring the latest technology and the concept of “full life cycle eye health management” into the homes of ordinary people. Among them, VisuMax’s core technology “chirped pulse amplification technology” won the 2018 Nobel Prize in Physics, providing a new treatment method for refractive surgery.
On the other hand, as the situation of myopia prevention and control in Chinese children and adolescents is becoming more and more severe, Zeiss has set up a special team for the prevention and control of myopia in China, paying close attention to the high incidence of myopia in children and adolescents, the younger age of myopia, and the resulting eye diseases, schooling and employment, etc. question. The company plans to create an overall solution for myopia prevention and control through a digital platform, an excellent operation center and a new matrix of myopia products; at the same time, it will further deepen the cooperation with top local medical and scientific research institutions to jointly promote the standardization and precision of myopia diagnosis and treatment process. Zeiss will present the latest achievements of the project to the public at this CIIE.
As a global innovation pioneer in the field of optics and optoelectronics, since Zeiss entered China in 1957, it has always been close to local customers and industry development, and achieved common growth through close cooperation. With the world’s leading technological advantages, product portfolios and solutions covering the entire industry chain, and 175 years of innovation experience, Zeiss will continue to deepen the Chinese market and continue to create value for partners from all walks of life; Urgent needs for scientific research innovation, manufacturing upgrades and improving the quality of life.
About the ZEISS Group
ZEISS is a global technology pioneer in optics and optoelectronics. In the last fiscal year, the Zeiss Group’s annual revenue totaled 6.3 billion euros, covering the four business sectors of semiconductor manufacturing technology, industrial quality and research, medical technology, and optical consumer goods (data as of September 30, 2020).
ZEISS develops, manufactures and markets innovative industrial measurement and quality assurance solutions for its customers, microscopy solutions for biology and materials science, and medical technology solutions for ophthalmology and microsurgery. Zeiss is also the global industry benchmark for lithography technology, which is used by the chip industry in the manufacture of semiconductor components. In addition, innovative products such as eyeglass lenses, camera lenses and binoculars under the Zeiss brand are also available worldwide.
ZEISS’ product portfolio is in line with future growth areas such as digitalization, healthcare and smart manufacturing, and it also has a strong brand. With this, ZEISS is shaping the future of technology and continues to advance optics and related fields with its solutions. The company’s sustainable and substantial investment in research and development has laid a solid foundation for the company’s success, the continuous expansion of ZEISS technology and its market leadership. Zeiss invests 12% of its revenue in R&D – such a high level of R&D investment has a long tradition at Zeiss and is an investment in the future.
ZEISS has about 34,000 employees worldwide, about 30 production sites, nearly 60 sales and service companies and 27 R&D institutions in nearly 50 countries. The company was founded in Jena in 1846 and is headquartered in Oberkochen, Germany. Carl Zeiss AG is wholly owned (as of March 31, 2021) by the Carl Zeiss Foundation, which is dedicated to advancing science in Germany.
The Links: 2MBI400TC-060 LTM150XP-L01
